BKA
EW icon

Brick & Kyle Associates’s Edwards Lifesciences EW Stock Holding History

Brick & Kyle Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-300
Closed -$9K – 178
2017
Q1 		$9K Hold
300
– – 0.01% 350
2016
Q4 		$9K Hold
300
– – 0.01% 351
2016
Q3 		$12K Hold
300
– – 0.01% 330
2016
Q2 		$10K Buy
+300
New +$10.3K 0.01% 345

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Brick & Kyle Associates's EW Position: Q2 2017 in Review

Brick & Kyle Associates sold out of Edwards Lifesciences (EW) in Q2 2017, closing a stake of 300 shares — an estimated $9K sold.

Brick & Kyle Associates first reported a position in EW in Q2 2016 and held it in 4 quarters. The position peaked at $12K in Q3 2016. 720 funds tracked by Wall St. Rank hold EW as of Q2 2017.

  • Brick & Kyle Associates reported no remaining Edwards Lifesciences position as of Q2 2017 after selling out during the quarter.
  • Brick & Kyle Associates sold 300 Edwards Lifesciences shares in Q2 2017, an estimated $9K.
  • Brick & Kyle Associates first reported a position in Edwards Lifesciences in Q2 2016 and held it in 4 quarters.
  • Brick & Kyle Associates's Edwards Lifesciences position peaked at $12K in Q3 2016.
  • 720 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.